The Sanofi-backed vaccine developer has filed to float on the Nasdaq Global Select Market and set a placeholder target of $100m.
Icosavax, a US-based vaccine developer that counts pharmaceutical firm Sanofi as an investor, has filed for an initial public offering on the Nasdaq Global Select Market with a $100m placeholder target.
Founded in 2017, Icosavax is working on vaccines for infectious diseases that cause life-threatening respiratory illnesses. Its product pipeline includes IVX-A12 and IVX-411, candidates aimed at respiratory syncytial virus and Sars-CoV-2, respectively.
Proceeds from the offering would go towards the continued development of its pipeline, progressing IVX-A12 through…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
